%0 Consensus Development Conference
%T Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
%A Nash P
%A Kerschbaumer A
%A Dörner T
%A Dougados M
%A Fleischmann RM
%A Geissler K
%A McInnes I
%A Pope JE
%A van der Heijde D
%A Stoffer-Marx M
%A Takeuchi T
%A Trauner M
%A Winthrop KL
%A de Wit M
%A Aletaha D
%A Baraliakos X
%A Boehncke WH
%A Emery P
%A Isaacs JD
%A Kremer J
%A Lee EB
%A Maksymowych WP
%A Voshaar M
%A Tam LS
%A Tanaka Y
%A van den Bosch F
%A Westhovens R
%A Xavier R
%A Smolen JS
%J Ann Rheum Dis
%V 80
%N 1
%D 01 2021
%M 33158881
%F 27.973
%R 10.1136/annrheumdis-2020-218398
%X Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety.<BR>Existing data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi. The committee included patients, rheumatologists, a gastroenterologist, a haematologist, a dermatologist, an infectious disease specialist and a health professional. The SLR informed the Task Force on controlled and open clinical trials, registry data, phase 4 trials and meta-analyses. In addition, approval of new compounds by, and warnings from regulators that were issued after the end of the SLR search date were taken into consideration.<BR>The Task Force agreed on and developed four general principles and a total of 26 points for consideration which were grouped into six areas addressing indications, treatment dose and comedication, contraindications, pretreatment screening and risks, laboratory and clinical follow-up examinations, and adverse events. Levels of evidence and strengths of recommendations were determined based on the SLR and levels of agreement were voted on for every point, reaching a range between 8.8 and 9.9 on a 10-point scale.<BR>The consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management.